News & Updates

A four-drug combination that includes either empagliflozin or dapagliflozin helps keep glucose in check through 3 years for patients with type 2 diabetes (T2D), in addition to its positive effect on weight and tolerable safety profile, as shown in an open-label randomized controlled study.

Pregnant women with gestational diabetes mellitus (GDM) who are overweight and have increased blood glucose, as measured by the Oral Glucose Tolerance Test (OGTT), are highly likely to require subsequent insulin therapy, according to a study.

Although a viable treatment option in patients with diabetes complicated by end-stage renal disease, pancreas transplant alone in uraemic (PTAU) patients confers inferior survival, graft survival, and immunological outcomes relative to simultaneous pancreas-kidney (SPK) transplant, a recent study has found.

Among women with obesity and atypical hyperplasia or low-risk endometrial cancer, weight loss during conservative management with intrauterine progestin improves treatment outcomes, according to a study.

Among healthy individuals, a fasting plasma glucose (FPG) concentration within the range of 90–99 mg/dL increases the risk of type 2 diabetes, a new Japan study has found.

Among patients with type 2 diabetes (T2D), women appear to be at greater risk of accelerated cognitive decline than men, as reported in a study. This risk increase can be partly explained by depressive symptoms being greater among women.

Individuals with long-term metabolic syndrome are at increased risk of developing gastrointestinal cancer overall, including colorectal and pancreatic cancers and hepatocellular carcinoma, with the risk increase independent of genetic predisposition, a study has found.

Ertugliflozin, a novel sodium-glucose cotransporter inhibitor, helps reduce glycated haemoglobin (HbA1c), body weight, and fasting plasma glucose (FPG) in patients with type 2 diabetes, reports a recent meta-analysis.